The Outlook for Pharmaceutical Markets in Northern Europe is a unique collection of management reports from Espicom Business Intelligence. Each report provides individual and highly-detailed analysis of each market, looking at the key regulatory, political, economic and corporate developments in the wider context of market structure, service and access. The reports are available individually, or as a discounted collection. 7 Key Markets Covered!
Denmark, Estonia, Finland, Latvia,
Lithuania, Norway and Sweden. Highlights from the region: DENMARK
Due to the presence of Novo Nordisk, Denmark is a major global supplier of insulin in retail form. This has resulted in a long standing balance of trade surplus. Imports and exports have experienced double-digit growth since 2000. The balance of trade surplus was in excess of US$3.3 billion in 2004. Parallel imported products constitute 10.2% of pharmaceuticals consumed in the primary sector, with a third of respiratory drugs being parallel imported.

Although companies are free to set their own prices, products will only be reimbursed at the level of the lowest generic drug in each class unless it can be shown that there is a distinct therapeutic benefit. The government hopes that this will limit the number of ‘me-too' products that would previously have been reimbursed.

SWEDEN
The Swedish pharmaceutical market represents approximately 14.1% of total healthcare expenditure and 1.2% of GDP. The market is expected to increase at a rate of 4.6% per year at current dollar prices over the next few years, to be worth in excess of US$5.4 billion by 2011.

As is common with other western European countries, Sweden has an advanced healthcare system which is partially privately funded. As a percentage of GDP, health expenditure is above the European average.

NORWAY
Although Norway is not part of the European Union, the process for pharmaceutical registration has been aligned to EU regulations. The relative ease of entry to the Norwegian market has enabled foreign companies to set up manufacturing plants, especially since the increased transparency in the pharmaceutical pricing structure.

Since generic substitution was established in 2001, generic drugs have been able to gain an increasing share of the market, in terms of value and volume. In 2005, generics had 30.5% of sales and 54.2% of the market by volume.

LITHUANIA
Around 80% of the Lithuanian pharmaceutical market is supplied by imports. In 2004, Germany, Latvia and Belgium were the leading suppliers, accounting for almost 50% of imports. The value of imports has increased every year since 1999.

The Lithuanian pharmaceutical industry has failed to attract the interest of foreign manufacturers, unlike other new EU member states, such as Poland or Hungary. A recent legislative change, which makes it difficult for new companies to acquire import licences, may further dissuade pharmaceutical companies from setting up in Lithuania. Sanitas, the largest Lithuanian pharmaceutical company, has more than doubled its sales figures by acquiring two pharmaceutical companies in Central Europe. Sanitas purchased Slovakia's Hoechst-Biotika in July 2005 and Poland's Jelfa in April 2006. Sales grew by 174.1% between June 2005 and June 2006 as a result.

ESTONIA
In 2006, the Estonian market for pharmaceuticals is estimated at US$214 million, or US$160 per capita. It is expected that the market will continue to expand at a rate of 7.4% per annum, reaching US$306 million, or US$232 per capita by 2011.

Around 85% of the pharmaceutical market is supplied by imports. Germany, Switzerland and Denmark were the leading suppliers in 2004, accounting for over 30% of imports. The value of imports has increased every year since 1999, following a slight decline. FOR EVERY MARKET
MARKET OUTLOOK
Current market size
Unique 5-Year market projections to 2012
Market outlook
Comment & rating, covering 8 key areas such as use of generic drugs, intellectual property, pricing and the health systems
Market structure
Statistical data on imports and exports
Market developments, covering recent and impending developments with respect to key issues such as regulation, health facilities, funding and
government policy
Key national data projections

FOR EVERY MARKET

BACKGROUND DATA
Population data, including growth trends and age structure
Demographic indicators detailing principal causes of death and morbidity

HEALTHCARE SYSTEM
Organisation & administration
Health expenditure
- Expenditure by source of funding and type
Hospital services
- Hospital data such as beds by type, region, specialty, patient admissions and surgical procedures
Outpatient care
Medical personnel
- Data on healthcare professionals covering such areas as doctors by specialty, nursing staff and dentists

ACCESSING THE PHARMA MARKET
Regulatory environment
Distribution guide and trade fair information
Domestic production

CONTACT DETAILS
For healthcare organisations and trade associations